Jim Silverman is the managing member of RRC Bio Fund LP, a Boston-based hedge fund focused on small-cap biotech. RRC Bio was launched in 2007. Silverman also founded Risk/Reward Capital Management in 1997, a registered investment advisory. He lives in Cambridge, Mass., and received a BBA in finance from The George Washington University.
Recent Articles By The Author
Ariad Pharma: The Contrarian Long Thesis
Iclusig may find use in other cancers and '113 is better than the market believes.
Cell Therapeutics: Addicted to Reverse Stock Splits
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
Programmed Insider Buying? Yes, at Insmed and United Therapeutics
Instead of selling stock whenever the wind blows, biotech execs should be buying.
He's Baaaaack . . .
With President Obama re-elected it's back to discussing changes to the tax code and the effect on dividends.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data
How best to invest in the next important clinical trial catalyst facing Celgene.